Table 9. Therapies Available in the Newly Diagnosed/Relapsed Refractory Setting for Waldenström Macroglobulinemia.

Regimen	Response rate	Time to response	PFS	OS	Author
Rituximab, cyclophosphamide, vincristine, prednisone	50%				Wechalekar et al. (2008)
Rituximab, bortezomib, dexamethasone	85%	3 mo	43 mo	66% at 8 years	Gavriatopoulou et al. (2017)
Rituximab, bortezomib, dexamethasone	96%	1.4 mo	57% at 5 years	95% at 5 years	Treon et al. (2015a)
Bortezomib, rituximab	88%	3.7 mo	37 mo	94% at 5 years	Ghobrial et al. (2010)
Ixazomib, rituximab, dexamethasone	96%	2 mo	73% at 22 mo	100% at 2 years	Castillo et al. (2018)
Carfilzomib, rituximab, dexamethasone	87%	2.1 mo	64.5% at 15 mo	NR	Treon et al. (2014)
Rituximab, bendamustine (subgroup analysis)	95%	NR	69 mo	90.4% at 5 years	Rummel et al. (2013)
Rituximab, cyclophosphamide, dexamethasone	83%	4 mo	36 mo	96 mo	Kastritis et al. (2015)
Ibrutinib	90.5%	1 mo	60% at 5 years	87% at 5 years	Treon et al. (2015b)
Ibrutinib, rituximab	92%	1 mo	82% at 30 mo	94% at 30 mo	Dimopoulos et al. (2018)
Acalabrutinib	79%	4.6 mo	90% at 24 mo		Owen et al. (2020)
Zanubrutinib	74%	2.8 mo; time to response longer in those with CXCR mutation	78% at 18 mo	97% at 18 mo	Tam et al. (2020)
Venetoclax	81%	5.1 mo	30 mo	NR	Castillo et al. (2022)